Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation

INTRODUCTION: Risankizumab has demonstrated efficacy and safety in phase 3 studies in patients with moderate to severe plaque psoriasis. This randomized clinical trial assessed the efficacy and safety of risankizumab in patients with moderate to severe plaque psoriasis in the Russian Federation. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Odnopozova, Liudmila, Edin, Anton, Sukharev, Alexey, Wu, Tianshuang, Aydin, Kerstin, Kelly, Maureen, Khotko, Alkes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464287/
https://www.ncbi.nlm.nih.gov/pubmed/35917057
http://dx.doi.org/10.1007/s13555-022-00776-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464287/
https://www.ncbi.nlm.nih.gov/pubmed/35917057
http://dx.doi.org/10.1007/s13555-022-00776-0

Ejemplares similares